Cite

HARVARD Citation

    Park, S. et al. (2021). Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study. Diabetes, obesity & metabolism. 23 (6), pp. 1232-1241. [Online]. 
  
Back to record